Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum

Respiratory Medicine

Volumn 101, Issue 8, 2007, Pages 1687-1695

  Bons, Judith A ^a   Drent, Marjolein ^a   Bouwman, Freek G ^b   Mariman, Edwin C ^b   van Dieijen Visser, Marja P ^a   Wodzig, Will K ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Fractionation; Identification; Multimarker; Proteomics; SELDI TOF MS; Serological markers

Indexed keywords

BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HAPTOGLOBIN; INTERLEUKIN 2 RECEPTOR;

ADULT; ALGORITHM; ANION EXCHANGE; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG SARCOIDOSIS; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; SARCOIDOSIS, PULMONARY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34250681887     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.03.002     Document Type: Article

References (49)

1. Baughman R.P., Lower E.E., and Du Bois R.M. Sarcoidosis. Lancet 361 (2003) 1111-1118
2. Kataria Y.P., and Holter J.F. Sarcoidosis: a model of granulomatous inflammation of unknown etiology associated with a hyperactive immune system. Methods 9 (1996) 268-294
3. Judson M.A., Baughman R.P., Thompson B.W., Teirstein A.S., Terrin M.L., Rossman M.D., et al. Two year prognosis of sarcoidosis: the access experience. Sarcoidosis Vasc Diffuse Lung Dis 20 (2003) 204-211
4. Rybicki B.A., Maliarik M.J., Major M., Popovich Jr. J., and Iannuzzi M.C. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect 13 (1998) 166-173
5. Baughman R.P., Winget D.B., Bowen E.H., and Lower E.E. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 14 (1997) 154-158
6. Arcasoy S.M., Christie J.D., Pochettino A., Rosengard B.R., Blumenthal N.P., Bavaria J.E., et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 120 (2001) 873-880
7. Anderson N.L., and Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteom 1 (2002) 845-867
8. Srinivas P.R., Verma M., Zhao Y., and Srivastava S. Proteomics for cancer biomarker discovery. Clin Chem 48 (2002) 1160-1169
9. Hutchens T.W., and Yip T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 7 (1993) 576-580
10. Petricoin III E.F., Mills G.B., Kohn E.C., and Liotta L.A. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360 (2002) 170-171
11. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
12. Kozak K.R., Amneus M.W., Pusey S.M., Su F., Luong M.N., Luong S.A., et al. Identification of biomarkers for ovarian cancer using strong anion-exchange proteinchips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 100 (2003) 12343-12348
13. Zhang Z., Bast Jr. R.C., Yu Y., Li J., Sokoll L.J., Rai A.J., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64 (2004) 5882-5890
14. Vlahou A., Schorge J.O., Gregory B.W., and Coleman R.L. Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J Biomed Biotechnol 2003 (2003) 308-314
15. Ye B., Cramer D.W., Skates S.J., Gygi S.P., Pratomo V., Fu L., et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9 (2003) 2904-2911
16. Rai A.J., Zhang Z., Rosenzweig J., Shih Ie M., Pham T., Fung E.T., et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126 (2002) 1518-1526
17. Banez L.L., Prasanna P., Sun L., Ali A., Zou Z., Adam B.L., et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 170 (2003) 442-446
18. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62 (2002) 3609-3614
19. Petricoin III E.F., Ornstein D.K., Paweletz C.P., Ardekani A., Hackett P.S., Hitt B.A., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94 (2002) 1576-1578
20. Qu Y., Adam B.L., Yasui Y., Ward M.D., Cazares L.H., Schellhammer P.F., et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48 (2002) 1835-1843
21. Li J., White N., Zhang Z., Rosenzweig J., Mangold L.A., Partin A.W., et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol 171 (2004) 1782-1787
22. Zhukov T.A., Johanson R.A., Cantor A.B., Clark R.A., and Tockman M.S. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by seldi mass spectrometry. Lung Cancer 40 (2003) 267-279
23. Poon T.C., Hui A.Y., Chan H.L., Ang I.L., Chow S.M., Wong N., et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis b infection by serum proteomic fingerprinting: a pilot study. Clin Chem 51 (2005) 328-335
24. Zhu X.D., Zhang W.H., Li C.L., Xu Y., Liang W.J., and Tien P. New serum biomarkers for detection of hbv-induced liver cirrhosis using seldi protein chip technology. World J Gastroenterol 10 (2004) 2327-2329
25. Kriegova E, Melle C, Kolek V, Hutyrova B, Mrazek F, Bleul A, et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2006.
26. Magi B., Bini L., Perari M.G., Fossi A., Sanchez J.C., Hochstrasser D., et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 23 (2002) 3434-3444
27. Sabounchi-Schutt F., Astrom J., Hellman U., Eklund A., and Grunewald J. Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. Eur Respir J 21 (2003) 414-420
28. Sabounchi-Schutt F, Mikko M, Eklund A, Grunewald J, Astrom J. Serum protein pattern in sarcoidosis analysed by a proteomics approach. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:182-90.
29. Song Z., Marzilli L., Greenlee B.M., Chen E.S., Silver R.F., Askin F.B., et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 201 (2005) 755-767
30. Ziegenhagen M.W., Rothe M.E., Schlaak M., and Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 21 (2003) 407-413
31. Muller-Quernheim J. Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology. Sarcoidosis Vasc Diffuse Lung Dis 15 (1998) 22-37
32. Rothkrantz-Kos S., van Dieijen-Visser M.P., Mulder P.G., and Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 49 (2003) 1510-1517
33. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
34. Bons J.A., de Boer D., van Dieijen-Visser M.P., and Wodzig W.K. Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. Clin Chim Acta 366 (2006) 249-256
35. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 16 (1993) 5-40
36. Hunninghake G.W., Costabel U., Ando M., Baughman R., Cordier J.F., Du Bois R., et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999) 149-173
37. DeRemee R.A. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest 83 (1983) 128-133
38. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
39. Solassol J., Marin P., Demettre E., Rouanet P., Bockaert J., Maudelonde T., et al. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal Biochem 338 (2005) 26-31
40. Linke T., Ross A.C., and Harrison E.H. Profiling of rat plasma by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, a novel tool for biomarker discovery in nutrition research. J Chromatogr A 1043 (2004) 65-71
41. Liu W., Guan M., Wu D., Zhang Y., Wu Z., Xu M., et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 47 (2005) 456-462
42. Bouwman F., Renes J., and Mariman E. A combination of protein profiling and isotopomer analysis using matrix-assisted laser desorption/ionization-time of flight mass spectrometry reveals an active metabolism of the extracellular matrix of 3t3-l1 adipocytes. Proteomics 4 (2004) 3855-3863
43. Bouwman F., Suylen D., Renes J., and Mariman E. Evaluation and improving the success rate of protein identification by peptide mass fingerprinting using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 19 (2005) 2465-2468
44. Grutters J.C., Fellrath J.-M., Mulder L., Janssen R., Van Den Bosch J.M.M., and van Velzen-Blad H. Serum sil2r measurement in sarcoidosis patients: a clinical evaluation. Chest 124 (2003) 186-195
45. Koopmann J., Zhang Z., White N., Rosenzweig J., Fedarko N., Jagannath S., et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10 (2004) 860-868
46. Jock CA, Paulauskis JD, Baker D, Olle E, Bleavins MR, Johnson KJ, et al. Influence of matrix application timing on spectral reproducibility and quality in SELDI-TOF-MS. Biotechniques. 2004;37:30-2, 34.
47. Cordingley HC, Roberts SL, Tooke P, Armitage JR, Lane PW, Wu W, et al. Multifactorial screening design and analysis of SELDI-TOF proteinchip array optimization experiments. Biotechniques 2003;34:364-5, 368-73.
48. Langlois M.R., and Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42 (1996) 1589-1600
49. Dhaliwal G., Cornett P.A., and Tierney L.M. Hemolytic anemia. Am Fam Physician 69 (2004) 2599-2606